NEW YORK, May 25, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced that its virtual-only Annual Meeting of Shareholders will be held at 5:00 PM ET on June 8, 2022.
To participate in the Annual Shareholders Meeting, shareholders should visit https://central.virtualshareholdermeeting.com/INKT2022 and enter the 16-digit control number found in their proxy materials. Guests may participate in a listen-only mode. No control number is required for guests. Registration for all attendees will start at 4:45 PM ET.
Webcast Information:
Date: Wednesday, June 8, 2022
Time: 5:00 PM ET
A live webcast and replay will be accessible from the Company's website at https://investor.minktherapeutics.com/events-and-presentations and at https://central.virtualshareholdermeeting.com/INKT2022.
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next-generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, please visit https://minktherapeutics.com/.
Contact
Ethan Lovell
Chief External Affairs & Communications
339-927-1763
ethan.lovell@agenusbio.com
Media Relations
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com
